Anders Holm joined Zelluna Immunotherapy in May 2017 and serves as Chief Operating Officer. Prior to joining Zelluna, Anders was Technology Strategy Manager at Inven2 which is the technology transfer office of Oslo University Hospital, where he was responsible for a large portfolio of drug development projects within immunology and immuno-oncology. One of his projects was preparation of the technology base, business case and initial funding for Zelluna. He also co-headed the successful commercialization of GnRH antagonists in treatment of autoimmune diseases, which is currently in clinical development. Anders previously worked for 8 years as a scientist at the Institute of Immunology, Oslo University Hospital, primarily within the fields of autoimmunity and cancer. Anders received his PhD in analytical chemistry at the University of Oslo in 2004.